Document is current
Any future updates will be listed below
-
Authors
Fanciulli, Alessandra https://orcid.org/0000-0002-2854-4179
Sixel-Döring, Friederike
Buhmann, Carsten
Krismer, Florian
Hermann, Wiebke
Winkler, Christian
Woitalla, Dirk
Jost, Wolfgang H.
,
Bähr, Mathias
Becktepe, Jos
Berg, Daniela
Brockmann, Kathrin
Ceballos-Baumann, Andrés
Claßen, Joseph
Deuschl, Cornelius
Deuschl, Günther
Dodel, Richard
Ebersbach, Georg
Beelitz-Heilstätten,
Eggers, Carsten
van Eimeren, Thilo
Fimm, Bruno
Folkerts, Ann-Kristin
Gausepohl, Madeleine
Segeberg, Bad
Hasan, Alkomiet
Hilker-Roggendorf, Rüdiger
Höllerhage, Matthias
Hopfner, Franziska
Jost, Wolfgang
Kalbe, Elke
Kassubek, Jan
Klebe, Stephan
Klein, Christine
Klietz, Martin
Köglsperger, Thomas
Kühn, Andrea
Krack, Paul
Krismer, Florian
Kuhlenbäumer, Gregor
Levin, Johannes
Liepelt-Scarfone, Inga
Lingor, Paul
Loewenbrück, Kai
Löhle, Matthias
Lorenzl, Stefan
Maaß, Sylvia
Maetzler, Walter
Menzel, Regina
Meyer, Philipp T.
Mollenhauer, Brit
Neumann, Manuela
Odin, Per
Outeiro, Tiago
Pötter-Nerger, Monika
Reese, René
Reetz, Kathrin
Rieß, Olaf
Ruf, Viktoria
Schneider, Anja
Schrader, Christoph
Schnitzler, Alfons
Seppi, Klaus
Storch, Alexander
Tönges, Lars
van Eimeren, Thilo
Walter, Uwe
Wächter, Tobias
Warnecke, Tobias
Wegner, Florian
Witt, Karsten
Woitalla, Dirk
Zeuner, Kirsten
Trenkwalder, Claudia
Höglinger, Günter
-
Funding
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
- License Information
-
More Information
Article History
Received: 8 August 2024
Revised: 15 November 2024
Accepted: 17 November 2024
First Online: 3 January 2025
Declarations
:
: A.F. reports royalties from Springer Verlag, speaker fees and honoraria from Bial, Theravance Biopharma, CNSystems, Medtronic, Sanofi, Broadview Ventures, Austrian Autonomic Society, Austrian Neurology Society, International Parkinson Disease and Movement Disorders Society, Elsevier and research grants from the FWF-Austrian Science Fund, Medical University of Innsbruck, Mission MSA and Dr Johannes and Hertha Tuba Foundation, outside of the present work. F.S.D. has nothing to disclose. C.B. reports fees for lectures and/or honor boards from AbbVie, Bial, Desitin, Kyowa Kirin, Merz, STADA Pharma, TAD Pharma, UCB, Zambon. He has received royalties from Thieme Press and Kohlhammer Press and reports funding from Hilde-Ulrichs-Stiftung für Parkinsonforschung.F.K. received personal fees from Institut de Recherches Internationales Servier, AbbVie, Takeda Pharmaceuticals, Sanofi, Teva, and Bial in the past 12 months, and he has ongoing grant support from the Austrian Science Fund (FWF) and the National Institutes of Health, outside of the submitted work. W.H. has nothing to disclose. C.W. has received honoraria for presentations or advisory boards from Abbvie, Bial, Licher MT, Stada, and UCB, outside of the present work. D.W. has received honoraria for presentations/advisory boards/consultations from Abbvie, UCB, STADA, Bial, Zambone, Esteve, outside of the present study. WHJ has received honoraria for presentations/advisory boards/consultations from Abbvie, Bial, Merz, Stada, Zambon, outside of the present study. C.T. has received funding from the DLR (German Research Association) by ERA-Net Project BRAVA (EU-Grant) outside the present study. She has received honoraria for presentations/advisory boards/consultations from Abbvie, UCB, STADA, Bial, Roche, Boehringer Ingelheim Pharma, Convatec, Esteve, Ono Pharmaceuticals outside the present study. She has received royalties from Thieme Publisher and licence fees for Parkinson Disease Sleep Scale-2. She has received travel stipends from the Movement Disorder Society. She serves as an editorial board member for Sleep Medicine. G.H. received research support from Abbvie, UCB; has ongoing research collaborations with Roche, UCB, Abbvie; serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon. He holds a patent (Höglinger GU, Höllerhage M, Rösler T. Treatment of Synucleinopathies. United States Patent No.: US 10,918,628 B2, Date of Patent: Feb. 16, 2021; and European Patent No.: EP 17 787 904.6–1109 / 3 525 788). He received publication royalties from Academic Press, Kohlhammer, and Thieme. He was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198); the German Federal Ministry of Education and Research (BMBF, CurePML EN2021-039, JPND consortium SynOD, 01ED2405A); European Joint Programme on Rare Diseases (Improve-PSP); Deutsche Forschungsgemeinschaft (DFG, HO2402/18-1 MSAomics); and participated in industry-sponsored research projects from Abbvie, Biogen, Biohaven, Novartis, Roche, Sanofi, UCB.
